Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
Asselah TarikStefan BourgeoisStephen PiankoStefan ZeuzemMark SulkowskiGraham R FosterLingling HanJohn McNallyAnu OsinusiDiana M BrainardG Mani SubramanianEdward J GaneJordan J FeldAlessandra MangiaPublished in: Liver international : official journal of the International Association for the Study of the Liver (2017)
Sofosbuvir plus velpatasvir is highly effective and safe for treating patients with hepatitis C virus genotypes 1, 2, 3, 4, 5 or 6 and advanced fibrosis or compensated cirrhosis.